Portnoy Law Firm Announces Class Action On Behalf Of Altimmune, Inc. Investors

2025-09-30 03:31:35

(MENAFN- GlobeNewsWire - Nasdaq) LOS ANGELES, Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Altimmune, Inc., ("Altimmune" or the "Company") (NASDAQ: ALT) investors of a class action on behalf of investors that bought securities between August 10, 2023, and June 25, 2025, inclusive (the“Class Period”). Altimmune investors have until October 6, 2025 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : ..., to discuss their legal rights, or join the case via . The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.

On June 26, 2025, Altimmune published a press release announcing topline results from the IMPACT Phase 2b MASH trial of Pemvidutide in the Treatment of MASH. While Altimmune had continuously provided inflated expectations ahead of these results, the analysis showed a pointed failure by the Company to achieve statistical significance in its analysis of the fibrosis reduction primary endpoint in its IMPACT Phase 2b MASH trial. In particular, while a positive trend in fibrosis improvement was observed, statistical significance was not met due to a higher-than-expected placebo response. When questioned about this concerning miss, the Company answered indifferently, attributing this result to the Phase 2 nature of the trial and stated that Altimmune was hoping for better results following the Phase 3 trial. On this news, Altimmune's stock price fell $4.10 per share, or 53.2%, to close at $3.61 per share on June 26, 2025.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
...
310-692-8883

Attorney Advertising

MENAFN30092025004107003653ID1110132782

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.